Yes - IMO - when comparing the data to the most successful topicals it is apparent that BTX1503 outperforms adapalene but not Epiduo, although the arm testing 2.5%BTX1503 QD is just 2.7 points behind Epiduo score (-13.3 to -16 mean change).
It is quite revealing to compare, that is data from the Phase 2 trial of a prescription topical that generates in excess of half a billion $US in revenues year after year.
It is also quite revealing to read some posters reactions.
DYOR
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-203
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |